Aurora Spine to Attend the American Association of Neurological Surgeons Annual Meeting
Aurora Spine Corporation (TSXV:ASG, OTCQB:ASAPF) has announced its participation in the 2023 AANS Annual Scientific Meeting from April 21-24, 2023, at the Los Angeles Convention Center, Booth #1011. The Company will showcase its innovative spinal surgery solutions, including the DEXA-C™ cervical cage, designed for anterior cervical discectomy with fusion (ACDF) procedures. DEXA-C uses patented DEXA Technology™ to align with patients' bone densities. Additionally, Dr. Sebastian Koga will present on April 23rd, discussing the advantages of 3D printed fusion devices. Aurora will also feature its SiLO TFX™ SI Fusion System for sacroiliac joint fusion and ZIP products for minimally invasive procedures. CEO Trent Northcutt expressed enthusiasm for engaging with leading neurosurgeons at the event.
- None.
- None.
Carlsbad, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that it will be attending the 2023 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting. The meeting will be held at April 21-24, 2023, at the Los Angeles Convention Center – Booth #1011.
At this year’s AANS event, Aurora Spine will be highlighting its product line, including DEXA-C™, a cervical cage for anterior cervical discectomy with fusion (ACDF) procedures. DEXA-C features Aurora's patented DEXA Technology™ that creates a series of implants manufactured with varying densities to match a patient's bone density and DEXA T-Score.
As part of the AANS meeting, Dr. Sebastian Koga, a neurosurgeon at Forrest Health Institute of Neuroscience, will deliver a presentation titled ‘Comparative Subsidence Analysis Between 3D Printed Bone Density Matched Titanium and PEEK Cervical Interbody Fusion Devices’ will be delivered on Sunday, April 23rd at 2pm.
The company will showcase its SiLO TFX™ SI Fusion System. The patented, minimally invasive SiLO TFX MIS Sacroiliac Joint Fixation System is intended for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. The SiLO TFX MIS Sacroiliac Joint Fixation System includes a Transfixing-Cone, an ilium screw, a sacrum screw and associated instrumentation. The SiLO TFX implants are designed to transfix the sacrum and ilium, providing stability for bony fusion. The company will also be displaying its line of ZIP products, which offer the Screwless Procedure and enables MIS Interspinous fusion without the use of a screw set.
Mr. Trent Northcutt, Aurora’s President, CEO and co-founder, stated, "We are excited to be attending this year’s AANS, where many of the country’s top neurological surgeons gather to learn about new products and procedures within the industry. This meeting is a great setting for Aurora to meeting up with doctors seeking newer technologies to incorporate into their procedures, like the DEXA-C, which has a proprietary design and technology, and can be used to match with a patient’s bone density, something other cages currently on the market do not consider. We are also looking forward to Dr. Koga’s presentation which will demonstrate the strength of the DEXA-C device and its superior performance to PEEK cages currently being implanted.”
About Aurora Spine
Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
Contact:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Chad Clouse
Chief Financial Officer
(760) 424-2004
Adam Lowensteiner
LYTHAM PARTNERS, LLC
Phoenix | New York
Telephone: 646-829-9700
FAQ
What is the date and location of the 2023 AANS Annual Scientific Meeting?
What product will Aurora Spine showcase at the AANS meeting?
Who will present at the 2023 AANS meeting and on what topic?
What are the key features of Aurora's SiLO TFX™ SI Fusion System?
What advantages does the DEXA-C™ cage offer compared to current market options?
